Hua-led medicine dorzagliatin joint Engli net treatment of refractory diabetes stage 1 results positive

As a dual-acting glucose kinase activator, dorzagliatin aims to control the development of progressive degenerative disease seditability by restoring blood glucose stabilization in patients with type 2 diabetesBy repairing deficiencies in glucose sensor function of glucose kinase, dorzagliatin has the potential to restore damaged blood glucose stability in people with type 2 diabetes, as a first-line treatment standard for the disease or as a basic treatment for combination with currently approved anti-diabetic drugsthe HMM0112 study, a Phase 1 clinical trial conducted in the United States, was designed to examine the pharmacokinetics (PK) and pharmacodynamics (PD) characteristics of dorzagliatin and SGLT-2 inhibitor engrenet alone or combined with drug use in patients with type 2 diabetes who were not able to effectively control blood sugar when taken alone or with a combination of drugspharmacokinetics studies showed that dorzagliatin or Englenet net combination of drugs did not affect their respective PK, supporting oral combination of drugsThe results of the pharmacodynamics study showed that the combined drug had a clear synergy effect: in the oral glucose tolerance test, dorzagliatin and Englinet net combination of drugs can effectively reduce the total blood sugar, the effect of reducing sugar is significantly better than the Engre net and dorzagliatin alone, in addition, the co-drug after the patient's C peptide secretion compared with the Nglin net single use significantly increasedDrChen Li, CEO ofHualed Pharmaceuticals,Dorzagliatin (Photo: durgbank.ca), said the results of the HMM0112 study showed that the combination with dorzagliatin improved the blood sugar control effect of SGLT-2 drugs on people with type 2 diabetes, thereby expanding the population of people with diabetes and significantly improving the islet function of patientsDorzagliatin is the core research product of Hualing Pharmaceuticals, which has now entered the phase 3 clinical research stageIn November 2019, Hualed Pharmaceuticals released the 24-week core findings of a Phase 3 registered clinical trial (HMM0301) to assess the effectiveness of dorzagliatin single-drug treatment for people with type 2 diabetes who have never been treated with medicationThe results of the 24-week study show that the clinical study of HMM0301 has reached the end of the main therapeutic endChina Collar Pharma will release its 52-week core data results by the end of the third quarter of this yearsingle-drug therapy, Huaguan Pharmaceuticals is also exploring the potential of combination of dorzagliatin and metformin, DPP-4 inhibitors, SGLT-2 inhibitors, insulin, GLP-1 receptor agonists and other type 2 diabetes drugs, and has made many research advancesThe 24-week patient visit edifying the 24-week-old clinical trial of phase 3 of the joint clinical trial of dorzagliatin and metformin for the treatment of type 2 diabetes, will publish the core 24-week core data results by the end of the third quarter of this year and the results of 52 weeks by the end of this year, according to a China-
Collar Pharmaceutical press releaseIn addition, dorzagliatin and THE DPP-4 inhibitor sigretin combined drug also demonstrated therapeutic advantages in the completed Phase 1 clinical studyIn another Phase 1 clinical study, dorzagliatin also showed the potential of medication in patients with end-stage chronic kidney diseaseReferences:Hua-Led Pharmaceuticals announces the successful results of a clinical study of dorzagliatin and Englinet (a SGLT-2 inhibitor) combined drugOrigind April 27, 2020, from https://mp.weixin.qq.com/s/oddMSIGqk3vrEy6uddu3LARetrieved Nov12, 2020, from https://original title: Fighting refractory diabetes! Hua-collar medicine dorzagliatin joint Engli net show treatment advantage